Get the Stockscreener App
193.59
0.66%
-1.3999
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $193.59, with a volume of 891.39K.
It is down -0.66% in the last 24 hours and down -5.40% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$194.99
Open:
$194.22
24h Volume:
891.39K
Relative Volume:
0.17
Market Cap:
$300.37B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
59.04
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
-3.88%
1M Performance:
-5.40%
6M Performance:
+138.85%
1Y Performance:
+160.92%
1-Day Range:
$192.31
$194.83
1-Week Range:
$189.35
$199.52
52-Week Range:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
193.69 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
996.88 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.28 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.41 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
155.69 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Franklin Resources Inc. Sells 1,585,664 Shares of AstraZeneca PLC $AZN - MarketBeat
Russell Investments Group Ltd. Has $66.19 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
In Brief: Jacobio/AZ’s JAB-23E73 Reports First Clinical Results For Pan-KRAS Inhibitors - Citeline News & Insights
Zoladex Market Is Booming Worldwide 2026-2033 | AstraZeneca, Pfizer, Ipsen, Novartis - openPR.com
Joshua Jackson, Gritty urge fans to get checked for cancer early - Stock Titan
AstraZeneca schedules digital annual general meeting for April 9 - Investing.com India
AstraZeneca schedules AGM for April 9, 2026 - Investing.com India
Capital International Inc. CA Buys 18,059 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu - marketscreener.com
AstraZeneca PLC $AZN Shares Sold by Victory Capital Management Inc. - MarketBeat
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment - GuruFocus
AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer - marketscreener.com
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns - GuruFocus
Legacy Capital Group California Inc. Buys New Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s AZD5004 Formulation Trial: Early Data Point for Long-Term Pipeline Value - TipRanks
AstraZeneca executives receive vested shares under deferred bonus plan - Investing.com India
AstraZeneca CEO Pascal Soriot receives vested shares under performance plan - Investing.com UK
AstraZeneca awards share grants to CEO and CFO under company incentive plans - Investing.com Nigeria
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca (NYSE: AZN) awards deferred bonus shares to leaders - Stock Titan
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial - Proactive financial news
Longfellow Investment Management Co. LLC Makes New Investment in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Raised by Orion Porfolio Solutions LLC - MarketBeat
AstraZeneca Executives Receive Vested Deferred Share Awards - TipRanks
AstraZeneca Grants Long-Term Share Awards to CEO and CFO - TipRanks
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop - Yahoo Finance
243,177 Shares in AstraZeneca PLC $AZN Purchased by Foresight Global Investors Inc. - MarketBeat
Top pharma companies racing to launch a weight-loss pill - Reuters
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca - Yahoo Finance
GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 - GlobeNewswire Inc.
Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha
HAP Trading LLC Sells 7,267 Shares of AstraZeneca PLC $AZN - MarketBeat
Mengis Capital Management Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Dimensional Fund Advisors LP Raises Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Position Lessened by Teachers Retirement System of The State of Kentucky - MarketBeat
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Inv - GuruFocus
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
CI Investments Inc. Has $18.33 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Advances Food-Effect Trial for New Cardio-Renal Combo Tablet - TipRanks
AstraZeneca (AZN) adds three fixed-rate US dollar note issues out to 2036 - Stock Titan
AstraZeneca PLC (AZN) Investor Outlook: Evaluating the Healthcare Giant Amidst a -21.01% Potential Downside - DirectorsTalk Interviews
Morqan Stanley Raises Astrazeneca Price Target to $219 From $109, Overweight Rating Kept - marketscreener.com
AstraZeneca reports total voting rights of over 1.55 billion shares - Investing.com
AstraZeneca (LSE/STO/NYSE: AZN) details 1.55B voting rights - Stock Titan
Fisher Asset Management LLC Acquires 466,745 Shares of AstraZeneca PLC $AZN - MarketBeat
ASTRAZENECA : JP Morgan maintains a Buy rating - marketscreener.com
Rafferty Asset Management LLC Sells 7,892 Shares of AstraZeneca PLC $AZN - MarketBeat
Becker Capital Management Inc. Decreases Position in AstraZeneca PLC $AZN - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review - marketscreener.com
American Century Companies Inc. Has $167.79 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):